您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Siltuximab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Siltuximab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:541502-14-1
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
CNTO-328
产品介绍
Siltuximab 是一种anti-IL-6(interleukin-6) 单克隆抗体,具有抗肿瘤活性。Siltuximab 可用于多中心性巨大淋巴结增生症 (MCD) 和 COVID-19 的研究。
生物活性

Siltuximab is an anti-IL-6(interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research[1][2][3].

体内研究
(In Vivo)

Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model[1].
Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model[4].

Animal Model:Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells[1]
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg; 3 times per week
Result:Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells.
Repressed PY-STAT3 levels in H1650 cells.
Inhibited the growth of tumors with H322 and CAF cells.
Inhibited the growth of tumors with H1650 and CAF cells.
Animal Model:Female NOD-SCID mice with MCF-7 tumor[4]
Dosage:20 mg/kg
Administration:Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
Result:Blocked MCF-7 engraftment, induced regressions in 90% of tumors.
Clinical Trial
性状

Liquid

CAS 号

541502-14-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.